Mind Medicine (MindMed) Inc. (MNMD): Price and Financial Metrics


Mind Medicine (MindMed) Inc. (MNMD): $2.70

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MNMD to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MNMD Stock Price Chart Interactive Chart >

Price chart for MNMD

MNMD Price/Volume Stats

Current price $2.70 52-week high $32.25
Prev. close $2.70 52-week low $2.35
Day low $2.64 Volume 227,100
Day high $2.74 Avg. volume 590,216
50-day MA $3.31 Dividend yield N/A
200-day MA $10.43 Market Cap 101.44M

Mind Medicine (MindMed) Inc. (MNMD) Company Bio


Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.


MNMD Latest News Stream


Event/Time News Detail
Loading, please wait...

MNMD Latest Social Stream


Loading social stream, please wait...

View Full MNMD Social Stream

Latest MNMD News From Around the Web

Below are the latest news stories about MIND MEDICINE (MINDMED) INC that investors may wish to consider to help them evaluate MNMD as an investment opportunity.

7 F-Rated Stocks to Sell Before We Reach Christmas

While you’re looking for the perfect holiday bargains to put under the tree, this is also an ideal time to clear your portfolio from F-rated stocks to sell.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | November 28, 2022

Activist Investor Informs MindMed of Financial Misstatements, Questions Internal Controls

SHERIDAN, Wyo., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Today, FCM MM HOLDINGS, LLC (“FCM”) announces that it has sent a letter (the “Letter”) to the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (“MindMed”, the “Company”). On November 10, 2022, MindMed filed with the Securities and Exchange Commission (the “SEC”) form 10-Q for quarter three of 2022 (the “ER”). The Letter focuses on false statements made by MindMed in the ER whereby MindMed, among other errors, underre

Yahoo | November 14, 2022

MindMed to Participate in the Jefferies London Healthcare Conference

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today announced that members of the Company's management team will participate in the Jefferies London Healthcare Conference, taking place in London, UK from November 15-17, 2022.

Yahoo | November 11, 2022

MindMed Reports Third Quarter 2022 Financial Results and Business Highlights

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, today reported its financial results for the quarter ended September 30, 2022.

Yahoo | November 10, 2022

Mind Medicine’s Bad Trip Won’t End Anytime Soon

Trouble abounds as Mind Medicine proposes a huge sale of MNMD stock shares and an activist investor threatens the company's board.

Louis Navellier and the InvestorPlace Research Staff on InvestorPlace | November 4, 2022

Read More 'MNMD' Stories Here

MNMD Price Returns

1-mo -7.85%
3-mo -77.02%
6-mo -82.69%
1-year -90.91%
3-year N/A
5-year N/A
YTD -86.96%
2021 -54.75%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6131 seconds.